Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline versus linezolid for acute bacterial skin and skin structure infection
2013-003644-23Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Apr 2015
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) comparing Omadacycline with Linezolid (2 arms). Primary endpoint: Primary efficacy outcome. Started Apr 2015; status: completed.
02
Drugs
omadacyclinelinezolid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on 2013-003644-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003644-23.